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Abstract 
Steroid biosynthesis is a complex process in which cholesterol is converted to steroid 
hormones with the involvement of multiple enzymes and cofactors. Inborn conditions 
affecting adrenal steroidogenesis are relatively common in paediatric practice and have 
serious implications on patient mortality and morbidity. This paper provides an overview of 
novel insights into human adrenal steroid biosynthesis. Inborn errors of steroidogenesis 
associated with congenital adrenal hyperplasia are discussed, with a particular focus on the 
pathophysiology and clinical features of 21-hydroxylase deficiency. The final section of the 
review presents more recent findings and clinical implications of adrenal-specific androgen 
biosynthesis. 
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Steroid hormone biosynthesis represents the multi-step enzymatic conversion of cholesterol via 
intermediate steroid precursors into biologically active steroid hormones. This biochemical 
process is regulated by a multitude of enzymes and co-factors. Due to their common origin from 
ĐŚŽůĞƐƚĞƌŽů ? ƐƚĞƌŽŝĚ ŚŽƌŵŽŶĞƐ Ăůů ƐŚĂƌĞ ƚŚĞ ƐĂŵĞ  ‘ƚĞƚƌĂĐǇĐůŝĐ ƐŬĞůĞƚŽŶ ? ? 
cyclopentanoperhydrophenanthrene [1]. Despite their structural similarities, from a functional 
perspective, these hormones constitute a heterogeneous group contributing to a wide range of 
essential physiological processes. 
 
The adrenal glands and the gonads are the principal organs involved in steroidogenesis. Other 
tissues with steroidogenic capacity include the placenta and the brain, which are well known sites 
of de novo steroid synthesis [1, 2]. Furthermore, the adipose tissue and the liver express a 
significant number of steroid-converting enzymes and therefore play important roles in the 
activation, metabolism and inactivation of steroid hormones [3]. The organs and tissues 
responsible for producing steroids express steroidogenic enzymes and co-factors differently, 
leading to site-specific variations and consequently pathways of steroid hormone synthesis [1]. 
Thus, the adrenal glands are primarily responsible for the synthesis of glucocorticoids and 
mineralocorticoids, as well as adrenal androgens, while the gonads represent the main site for 
the production of sex steroids, namely androgens, oestrogens and progesterone. 
 
Steroidogenic cells are defined by their capacity to produce steroids de novo using cholesterol as 
substrate, a process that requires the expression of the P450 side-chain cleavage enzyme 
(CYP11A1, P450scc). Most of the cholesterol used for steroid hormone biosynthesis originates 
from the uptake of plasma low density lipoproteins through endocytosis. However, many organs, 
including the adrenals, are capable of producing cholesterol de novo from acetate [1]. Within the 
adrenal cortex, the steroidogenic acute regulatory protein (StAR) plays an essential part by 
increasing the flow of cholesterol from the outer mitochondrial membrane to the inner 
mitochondrial membrane, where CYP11A1 initiates the first step of steroidogenesis. In contrast 
to polypeptide hormones, only minimal amounts of steroid hormones are stored in the 
steroidogenic glands and as such their release relies on rapid synthesis. This aspect has particular 
importance in the adrenal stress response, where steroidogenesis is a time-critical process. 
Steroid hormones are produced at a much slower rate in tissues that do not express StAR 
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(placenta and brain) through a process that is thought to involve proteins with StAR-like activity 
[1, 4]. 
 
Steroidogenic enzymes can be divided in two broad groups: cytochrome P450 (CYP) and 
hydroxysteroid dehydrogenases/ketosteroid reductase (HSD/KSR) [1]. Both play a major role in 
the biosynthesis of steroid hormones and a good knowledge of their structure and physiology is 
fundamental to understanding impaired steroidogenesis [1]. 
 
CYP enzymes contain a haeme prosthetic group that gives them the ability to activate molecular 
oxygen in order to catalyse oxidative reactions. They are functionally unidirectional, catalysing 
irreversibly the reactions they facilitate, with no feedback from downstream precursors [1].  CYP 
enzymes are subdivided in two types: type 1 enzymes being localised in the mitochondria and 
type 2 in the endoplasmic reticulum. Depending on their type CYP enzymes rely on different co-
factors: ferredoxin (FDX1) or adrenodoxin and ferredoxin reductase (FDXR) for CYP type 1 and 
P450 oxidoreductase (POR) for CYP type 2 enzymes. Six CYP enzymes are involved in 
steroidogenesis of which cholesterol side-chain cleavage enzyme (CYP11A1, P450scc), 11-
hydroxylase (CYP11B1, P450c11) and aldosterone synthase (CYP11B2, P450c11AS) belong to CYP 
type 1 enzymes, while 17-hydroxylase (CYP17A1, P450c17), 21-hydroxylase (CYP21A2, P450c21) 
and P450 aromatase (CYP19A1, P450aro) are CYP type 2 enzymes. Each CYP enzyme can 
metabolise more than one substrate and is thereby involved in multiple steps of 
steroidosynthesis. This impacts on the pathophysiology of inborn errors of steroidogenesis, such 
as 21-hydroxylase deficiency.  
 
HSD/KSR enzymes catalyse reversible reactions. However, while in vitro they can drive the 
reactions in both directions, in vivo they drive the steroid flux preferentially in the oxidative or 
reductive mode [1]. They require NADH/NAD+ or NADPH/NADP+ as co-factors for steroid 
reductions or oxidations. Based on their activity, HDS enzymes are classified into 
dehydrogenases, which use NAD+ to oxidate hydroxysteroids to ketosteroids, and reductases 
which use NADPH to reduce ketosteroids to hydroxysteroids. The HSDs involved in steroid 
synthesis and relevant to human pathology include the 3-hydroxysteroid dehydrogenase type 2 
(HSD3B2), the 11-hydroxysteroid dehydrogenase type 1 and type 2 (HSD11B1 and HSD11B2), and 
a series of 17-hydroxysteroid dehydrogenases (17-HSD) [1]. 
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Pathways of adrenal steroidogenesis  
The conversion of cholesterol to pregnenolone in the mitochondria represents the first step of 
steroidogenesis. This enzymatic process involves three chemical reactions and is catalysed by 
CYP11A1 (Figure 1). 
 
Mineralocorticoid synthesis 
In the adrenal zona glomerulosa, pregnenolone is irreversibly converted into progesterone by 
HSD3B2. Subsequently, CYP21A2 converts progesterone to 11-deoxycorticosterone (DOC). DOC 
serves as substrate for CYP11B2, which has 11-hydroxylase, 18-hydroxylase and 18-oxidase 
activities, thus catalysing the final three reactions leading to the production of aldosterone [5]. 
The adrenal zona glomerulosa has an enzymatic profile designed for mineralocorticoid synthesis 
and is the only zone to express CYP11B2. By contrast CYP17A1, the enzyme directing 
pregnenolone towards glucocorticoid and androgen synthesis, is present in very small amounts 
in zona glomerulosa [5]. 
 
Glucocorticoid synthesis  
Glucocorticoid synthesis occurs in the adrenal zona fasciculata, beginning with the 17-
hydroxylation of pregnenolone to 17-hydroxypregnenolone, catalysed by CYP17A1, which is also 
responsible for converting progesterone to 17-hydroxyprogesterone (17OHP). HSD3B2 converts 
17-hydroxypregnenolone to 17OHP, which is changed to 11-deoxycortisol by CYP21A2. Finally, 
CYP11B1 completes the process, converting 11-deoxycortisol to cortisol. 
 
Androgen synthesis 
Androgen synthesis takes place primarily in the adrenal zona reticularis and the gonads. 
Pregnenolone is converted to 17-hydroxypregnenolone, which in turn is converted to 
dehydroepiandrosterone (DHEA), reactions that are catalysed by CYP17A1, capable of both 17-
hydroxylase and 17,20-lyase activities [1]. The 17,20-lyase activity of CYP17A1 crucially relies on 
the co-factor cytochrome b5, which is only expressed in the zona reticularis. The main role of 
DHEA is as a precursor for active androgens [3]. It is converted to androstenedione by HSD3B2. 
However, a proportion of the DHEA synthesised is converted to DHEA sulphate (DHEAS), a 
reaction catalysed by sulphotransferase (SULT2A), which requires the presence of 3-
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phosphoadenosine-5-phosphosulfate synthase type 2 (PAPSS2) as a co-factor [1]. The sulphation 
of DHEA to DHEAS regulates the amount of DHEA available for androgen synthesis [6]. 
 
Two enzymes of the 17-hydroxysteroid dehydrogenase family are involved in androgen synthesis. 
Conversion of androstenedione to testosterone in the testes is catalysed by 17-hydroxysteroid 
dehydrogenase type 3 (HSD17B3), while 17-hydroxysteroid dehydrogenase type 5 or aldo-keto-
reductase C3 (17HSD5 or AKR1C3) is responsible for testosterone synthesis in the adrenals [7]. 
Testosterone is released into the circulation and activated in peripheral tissues to 
dihydrotestosterone (DHT) by  ?ɲ-reductase [3]. 
 
Adrenarche represents the onset of adrenal androgen synthesis following development of the 
zona reticularis, a gradual process that begins in early childhood from three to four years of age 
[8], but only becomes apparent from the age of six to eight years onwards [9]. The zona reticularis 
is characterised by an increased expression of the co-factor cytochrome b5 and of SULT2A, as 
well as decreased expression of HSD3B2, a combination favouring the synthesis of DHEA and 
DHEAS [3, 9]. dŚĞ ǁŝĚĞůǇ ƵƐĞĚ ƚĞƌŵ ŽĨ  “ƉƌĞŵĂƚƵƌĞ ĂĚƌĞŶĂƌĐŚĞ ? ďĞĨŽƌĞ ƚŚĞ ĂŐĞ ŽĨ  ? ǇĞĂƌƐ ŝƐ
usually based on clinical symptoms (pubarche, acne, apocrine body odor) and lacks biochemical 
confirmation due to non-sensitive assays that do not detect low concentrations of adrenal 
androgens in earlier life. 
 
Inborn errors of steroidogenesis  
Deficiencies in the main pathways of steroid biosynthesis have now been described for all major 
factors and steroidogenic enzymes and the inborn errors of steroidogenesis are well-defined 
conditions (Table 1). Steroid profiling using novel analytical strategies has made clinical diagnosis 
more straightforward [10-13]. 
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Enzyme/co-factor DSD Affected organ Deficiency Excess 
CYP21A2 46,XX Adrenal MC, GC SexH 
CYP11B1 46,XX Adrenal GC MC, SexH 
CYP17A1 46,XY Adrenal, gonad GC, SexH MC 
HSD3B2 46,XY (46,XX) Adrenal, gonad MC, GC, SexH  
POR 46,XY + 46,XX Adrenal, gonad, liver GC, SexH (MC) 
StAR 46,XY Adrenal, gonad MC, GC, SexH  
CYP11A1 46,XY Adrenal, gonad MC, GC, SexH  
CYP11B2 _ Adrenal MC  
 
Table 1. Clinical characteristics of inborn errors of steroidogenesis associated with 
congenital adrenal hyperplasia. CYP21A2: 21-hydroxylase, CYP11B1: 11-hydroxylase, 
CYP17A1: 17-hydroxylase, HSD3B2: 3-hydroxysteroid dehydrogenase type 2, POR: P450 
oxidoreductase, StAR: steroidogenic acute regulatory protein, CYP11A1: P450 side-chain 
cleavage enzyme, CYP11B2: aldosterone synthase, DSD: disorder of sex development, MC: 
mineralocorticoid, GC: glucocorticoid, SexH: sex steroid hormone, (MC): variable MC excess. 
 
Congenital adrenal hyperplasia (CAH) represents a group of inherited autosomal recessive 
diseases characterised by impaired adrenal steroid synthesis and in some cases impaired gonadal 
steroid production with associated genital ambiguity (Table 1). Seven inborn errors of 
steroidogenesis are commonly classified as CAH with 21-hydroxylase being the by far most 
common condition. The disorders included in the CAH group are defined by deficiencies of the 
following enzymes and co-factors: 21-hydroxylase (CYP21A2), 17-hydroxylase (CYP17A1), 11-
hydroxylase (CYP11B1), 3-hydroxysteroid dehydrogenase type 2 (HSD3B2), P450 oxidoreductase 
(POR), StAR (lipoid CAH) and P450 side-chain cleavage enzyme (CYP11A1) [14]. The absence of 
electron providing co-factor P450 oxidoreductase manifests with combined CYP17A1 and 
CYP21A2 deficiencies, as well as variable degrees of Antley-Bixler-like bone malformations [1, 
14]. Although CYP11B2 is commonly classified as a form of CAH, it does not truly belong to this 
group of conditions, as it only causes isolated aldosterone deficiency. This leads to salt-wasting 
crisis in infancy, however, patients who survive this stage often improve spontaneously and do 
not necessarily require replacement therapy in adulthood.  
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21-hydroxylase deficiency  
Steroid 21-hydroxylase deficiency (21OHD) accounts for more than 95% of CAH [14, 15]. It causes 
impaired synthesis of glucocorticoids and mineralocorticoids, with build-up of precursors, in 
particular 17OHP, that is the key precursor causing androgen excess. This process is amplified by 
the absence of the negative feedback of cortisol on ACTH secretion under physiological 
conditions. The severity of disease is dictated by the residual CYP21A2 activity. The clinical 
presentation is commonly divided into classic and non-classic 21OHD. Classic 21OHD is often 
subdivided in salt wasting (SW) and simple virilising (SV) forms, with the latter characterised by 
an in vitro 21-hydroxylase activity of 1-2% that prevents adrenal crisis in neonates [14]; whereas 
in non-classic 21OHD up to 50% of in vitro enzyme activity is preserved, leading to milder 
androgen excess which is clinically discrete or asymptomatic [14]. The utility of this classification 
has been questioned as all patients with 21OHD lose salt to some degree and there appears to 
be a continuum rather than binary 21OHD categories [16]. Impaired cortisol production causes 
androgen excess leading to antenatal virilisation of genetic females, precocious puberty in boys 
and rapid skeletal growth in both sexes, associated with early closure of growth plates and 
reduced final height. Patients with classic 21OHD require life-long treatment with glucocorticoids 
and mineralocorticoids. Unlike other forms of adrenal insufficiency, in 21OHD glucocorticoid 
treatment is aimed not only at replacing deficient cortisol, but also at suppressing excessive ACTH 
and androgen synthesis. These therapeutic goals remain challenging in clinical practice due to 
the circadian pattern of ACTH secretion and supraphysiological doses of glucocorticoids are often 
required. Consequently, many patients with 21OHD develop comorbidities associated with poor 
disease control and side effects of glucocorticoids, including impaired bone health, infertility, 
cardiovascular and metabolic disease [17, 18]. 
 
Alternative pathways of adrenal androgen synthesis 
Until recently, the adrenal contribution to circulating androgen hormones was mainly focused on 
DHEA and androstenedione and the potential of the adrenal cortex to produce testosterone. 
Both DHEA and androstenedione are weak androgens, serving as substrate for active androgen 
synthesis through peripheral conversion to testosterone and subsequently dihydrotestosterone 
(DHT) [19]. The evidence that has emerged over the last fifteen years regarding alternative 
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pathways to active androgens is now changing our understanding of adrenal pathology and will 
most likely change clinical management in the future. 
 
The alternative pathway to dihydrotestosterone 
Ŷ ĂůƚĞƌŶĂƚŝǀĞ ƉĂƚŚǁĂǇ ƚŽ ĂŶĚƌŽŐĞŶƐ ? ĨƌĞƋƵĞŶƚůǇ ĚĞƐĐƌŝďĞĚ ĂƐ  “ƚŚĞ ďĂĐŬĚŽŽƌ ƉĂƚŚǁĂǇ ? ? ŝƐ
represented by a chain of enzymatic reactions through which 17OHP is converted to DHT without 
testosterone as an intermediate [20]. 17OHP undergoes 5- then 3-reduction followed by 17,20-
lyase cleavage, resulting in androsterone. Androsterone is converted to DHT through 17-
reduction and 3-oxidation (Figure 2). It has been shown that this alternative pathway to 
androgens is active antenatally in healthy individuals and that it may play a role in male sex 
development during fetal life [20]. More recent evidence demonstrated its involvement in 
patients with 21OHD as a consequence of 17OHP excess [21]. Thus, it is believed that this 
alternative pathway contributes to androgen excess leading to the virilisation of the external 
genitalia of females with 21OHD. However, this alternative pathway of androgen synthesis was 
found to diminish after the first year of life in patients with 21OHD [21]. It may be that this is an 
explanation for the normal growth observed in patients during the first year of life [22], 
suggesting that a smaller dose of GC may be sufficient in young children with 21OHD [23]. The 
contribution of this alternative pathway to androgen excess has also been demonstrated in POR 
deficiency. This pathway partially explains virilisation of mothers during pregnancy in the 
presence of placental aromatase and the virilisation of female fetuses despite postnatal sex 
steroid deficiency [20]. 
 
Adrenal specific 11-oxygenated C19 steroids 
Another class of active adrenal androgens extensively studied in recent years are the 11-
oxygenated C19 steroids. Both androstenedione and testosterone undergo 11-hydroxylation, 
catalysed by CYP11B1, resulting in 11-hydroxyandrostenedione (11-OHA4) and 11-
hydroxytestosterone (11-OHT) respectively, which are then reduced by HSD11B2 to 11-
ketoandrostenedione (11-KA4) and 11-ketotestosterone (11-KT) respectively. 11-KT can be 5-
reduced to 11-ketodihydrotestosterone (11-KDHT) (Figure 1). 
 
Although 11-OHA4 ǁĂƐĚŝƐĐŽǀĞƌĞĚŝŶƚŚĞ ? ? ? ? ?Ɛ ?ŝƚreceived little attention as it was assumed to 
be part of an inactivating pathway for adrenal androgens [24]. However, more recent evidence 
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identified the 11-oxygentated C19 steroids as a distinct group of adrenal-derived androgens. 
While 11-OHA4 is a weak steroid that acts peripherally as a precursor for more active androgens 
[25], both 11-KT and 11-KDHT are very strong androgens transactivating the androgen receptor 
(AR) to a similar degree as DHT [26, 27]. Moreover, 11-KT appears to have an important 
physiological role during adrenarche, being the major circulating androgen in girls and women, 
followed by testosterone and 11-OHT [27]. There is also increasing evidence regarding the role 
of 11-oxygenated C19 androgens in adrenal androgen excess. High concentrations of 11-OHT, 11-
KT, 11-OHA4, 11-KA4 were found in patients with 21OHD compared to healthy controls [28] and 
it was suggested that these 11-oxygenated C19 steroids are major contributors to clinical 
androgen excess in children with CAH [29]. Importantly, in adults with 21OHD 11-oxygenated C19 
androgens were found to correlate with adrenal volume, an indicator of disease control [30]. 
Furthermore, it has been proposed that 11-oxygenated C19 steroids might serve as superior 
markers of adrenal androgen excess in CAH, compared to DHEA, androstenedione and 
testosterone, which are the commonly employed biomarkers for monitoring therapy control [28, 
31]. The clinical significance of 11-oxygenated C19 steroids has also been explored in polycystic 
ovary syndrome (PCOS), where 11-oxygenated C19 steroids are increased and correlate with 
markers of metabolic risk such as the body mass index (BMI) and the Homeostasis Model 
Assessment of Insulin Resistance (HOMA-IR) [32]. These findings indicate the potential clinical 
usefulness of this group of hormones and it can be anticipated that they will be introduced as 
biomarkers for monitoring of androgen excess in CAH in the future.  
 
Summary 
The diagnosis for most conditions affecting adrenal steroidogenesis is straightforward and 
deficiencies of all adrenal enzymes and almost all co-factors have been described in humans with 
distinct clinical phenotypes. However, recent advances have added multiple layers of complexity 
by defining additional pathways to active androgens to our understanding of steroidogenesis. 
Clinically the management of androgen excess remains a significant challenge. Greater insights 
into the role of alternative pathways of androgen synthesis have led to a better understanding 
of adrenal pathology and novel tests may be introduced into clinical practice in the future. In 
ƉĂƌƚŝĐƵůĂƌ ? ƚŚĞ  “ƌĞĚŝƐĐŽǀĞƌǇ ? ŽĨ  ? ?-oxygenated C19 steroids as potential markers of adrenal 
androgen excess carries the prospect of developing improved biomarkers of disease control for 
CAH patients with 21-hydroxylase deficiency.  
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List of abbreviations 1 
11-KA4: 11-ketoandrostenedione; 11-KDHT: 11-ketodihydrotestosterone; 11-KT: 11-2 
ketotestosterone; 11-OHA4: 11-hydroxyandrostenedione; 11-OHT: 11-hydroxytestosterone; 3 
17OHP: 17-hydroxyprogesterone; 17-HSD: 17-hydroxysteroid dehydrogenases; 21-S: 21-4 
deoxycortisol; 21OHD: 21-hydroxylase deficiency; 3HSD: 3-hydroxysteroid dehydrogenase; 5 
ADX/Adr: adrenodoxin/adrenodoxin reductase; AKR1C3 or 17HSD5: aldo-keto-reductase C3 6 
or 17-hydroxysteroid dehydrogenase type 5; AR: androgen receptor; CAH: congenital adrenal 7 
hyperplasia; CYP: cytochrome P450; CYP11A1 or P450scc: cholesterol side-chain cleavage 8 
enzyme; CYP11B1 or P450c11: 11-hydroxylase; CYP11B2 or P450c11AS: aldosterone synthase; 9 
CYP17A1 or P450c17: 17-hydroxylase; CYP19A1 or P450aro: P450 aromatase; CYP21A2 or 10 
P450c21: 21-hydroxylase; DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone 11 
sulphate; DHT: dihydrotestosterone; DOC: 11-deoxycorticosterone; H6PDH: hexose-6-12 
phosphate dehydrogenase; HSD/KSR: hydroxysteroid dehydrogenases/ketosteroid reductase; 13 
HSD11B1: 11-hydroxysteroid dehydrogenase type 1; HSD11B2: 11-hydroxysteroid 14 
dehydrogenase type 2; HSD17B3: 17-hydroxysteroid dehydrogenase type 3; HSD3B2: 3-15 
hydroxysteroid dehydrogenase type 2; NAD: nicotinamide adenine dinucleotide; NADPH: 16 
nicotinamide adenine dinucleotide phosphate (reduced form); PAPSS2: 3-phosphoadenosine-17 
5-phosphosulfate synthase type 2; PCOS: polycystic ovary syndrome; POR: P450 18 
oxidoreductase; StAR: steroidogenic acute regulatory protein; SULT2A: sulphotransferase. 19 
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Figure legends 
 
Figure 1. Diagram of adrenal steroid biosynthesis.  
The first and second columns represent mineralocorticoid and glucocorticoid synthesis. The third 
and fourth columns correspond to androgen synthesis, including synthesis of 11-oxygenated C19 
steroids. The large arrows indicate chemical reactions. The small arrows indicate the metabolites 
derived from the steroid hormones. Adjacent to each large arrow are the enzymes and co-factors 
involved in catalysing the respective reaction. Grey boxes are used to indicate steroidogenic 
enzymes, green boxes correspond to adrenodoxin/adrenodoxin reductase, orange box to 3-
phosphoadenosine-5-phosphosulfate synthase type 2, yellow ovals to P450 oxidoreductase, 
orange balls to cytochrome b5 and blue ovals to the coenzyme hexose-6-phosphate 
dehydrogenase. (abbreviations: THDOC: tetrahydro-11-deoxycorticosterone; THA: tetrahydro-
11-dehydrocorticosterone; THB: tetrahydrocorticosterone; THALDO: tetrahydroaldosterone; 
THS: tetrahydrodeoxycortisol; THF: tetrahydrocortisol). 
 
Figure 2. Diagram of the alternative pathway to dihydrotestosterone. 
The  “ĂůƚĞƌŶĂƚŝǀĞ ? ƉĂƚŚǁĂǇ ŝƐ ŝŶĚŝĐĂƚĞĚ ďǇ ƚŚĞ ƉĂůĞ-ďůƵĞ ďĂĐŬŐƌŽƵŶĚ ǁŚŝůĞ ƚŚĞ  “ĐůĂƐƐŝĐ ?
pathway is marked by the bright-blue background, both leading to dihydrotestosterone (grey-
blue background). The pink background marks the oestrogens pathway. The large arrows 
indicate chemical reactions. Adjacent to each arrow are the enzymes and co-factors involved 
in catalysing the respective reaction. Grey boxes are used to indicate steroidogenic enzymes 
and yellow ovals correspond to P450 oxidoreductase. 
